Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria

T. Majtan, W. Jones, J. Krijt, I. Park, WD. Kruger, V. Kožich, S. Bassnett, EM. Bublil, JP. Kraus,

. 2018 ; 26 (3) : 834-844. [pub] 20171219

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19012870

Classical homocystinuria (HCU) is the most common inherited disorder of sulfur amino acid metabolism caused by deficiency in cystathionine beta-synthase (CBS) activity and characterized by severe elevation of homocysteine in blood and tissues. Treatment with dietary methionine restriction is not optimal, and poor compliance leads to serious complications. We developed an enzyme replacement therapy (ERT) and studied its efficacy in a severe form of HCU in mouse (the I278T model). Treatment was initiated before or after the onset of clinical symptoms in an effort to prevent or reverse the phenotype. ERT substantially reduced and sustained plasma homocysteine concentration at around 100 μM and normalized plasma cysteine for up to 9 months of treatment. Biochemical balance was also restored in the liver, kidney, and brain. Furthermore, ERT corrected liver glucose and lipid metabolism. The treatment prevented or reversed facial alopecia, fragile and lean phenotype, and low bone mass. In addition, structurally defective ciliary zonules in the eyes of I278T mice contained low density and/or broken fibers, while administration of ERT from birth partially rescued the ocular phenotype. In conclusion, ERT maintained an improved metabolic pattern and ameliorated many of the clinical complications in the I278T mouse model of HCU.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012870
003      
CZ-PrNML
005      
20190416121242.0
007      
ta
008      
190405s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ymthe.2017.12.014 $2 doi
035    __
$a (PubMed)29398487
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Majtan, Tomas $u Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA. Electronic address: tomas.majtan@ucdenver.edu.
245    10
$a Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria / $c T. Majtan, W. Jones, J. Krijt, I. Park, WD. Kruger, V. Kožich, S. Bassnett, EM. Bublil, JP. Kraus,
520    9_
$a Classical homocystinuria (HCU) is the most common inherited disorder of sulfur amino acid metabolism caused by deficiency in cystathionine beta-synthase (CBS) activity and characterized by severe elevation of homocysteine in blood and tissues. Treatment with dietary methionine restriction is not optimal, and poor compliance leads to serious complications. We developed an enzyme replacement therapy (ERT) and studied its efficacy in a severe form of HCU in mouse (the I278T model). Treatment was initiated before or after the onset of clinical symptoms in an effort to prevent or reverse the phenotype. ERT substantially reduced and sustained plasma homocysteine concentration at around 100 μM and normalized plasma cysteine for up to 9 months of treatment. Biochemical balance was also restored in the liver, kidney, and brain. Furthermore, ERT corrected liver glucose and lipid metabolism. The treatment prevented or reversed facial alopecia, fragile and lean phenotype, and low bone mass. In addition, structurally defective ciliary zonules in the eyes of I278T mice contained low density and/or broken fibers, while administration of ERT from birth partially rescued the ocular phenotype. In conclusion, ERT maintained an improved metabolic pattern and ameliorated many of the clinical complications in the I278T mouse model of HCU.
650    _2
$a aminokyseliny sírové $x krev $x metabolismus $7 D000603
650    _2
$a zvířata $7 D000818
650    _2
$a cystathionin-beta-synthasa $x aplikace a dávkování $x chemie $7 D003541
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a preklinické hodnocení léčiv $7 D004353
650    12
$a enzymová substituční terapie $7 D056947
650    _2
$a glukosa $x metabolismus $7 D005947
650    _2
$a homocystinurie $x diagnóza $x metabolismus $x terapie $7 D006712
650    _2
$a metabolismus lipidů $7 D050356
650    _2
$a játra $x účinky léků $x metabolismus $7 D008099
650    _2
$a myši $7 D051379
650    _2
$a oxidační stres $7 D018384
650    12
$a fenotyp $7 D010641
650    _2
$a polyethylenglykoly $x chemie $7 D011092
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jones, Wendell $u Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA.
700    1_
$a Krijt, Jakub $u Department of Pediatrics and Adolescent Medicine, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague 12808, Czech Republic.
700    1_
$a Park, Insun $u Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA.
700    1_
$a Kruger, Warren D $u Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
700    1_
$a Kožich, Viktor $u Department of Pediatrics and Adolescent Medicine, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague 12808, Czech Republic.
700    1_
$a Bassnett, Steven $u Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA.
700    1_
$a Bublil, Erez M $u Orphan Technologies, Ltd., Rapperswil 8640, Switzerland.
700    1_
$a Kraus, Jan P $u Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA. Electronic address: jan.kraus@ucdenver.edu.
773    0_
$w MED00189556 $t Molecular therapy the journal of the American Society of Gene Therapy $x 1525-0024 $g Roč. 26, č. 3 (2018), s. 834-844
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29398487 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190416121307 $b ABA008
999    __
$a ok $b bmc $g 1392180 $s 1051175
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 26 $c 3 $d 834-844 $e 20171219 $i 1525-0024 $m Molecular therapy $n Mol Ther $x MED00189556
LZP    __
$a Pubmed-20190405
Back

Find record

Citation metrics

Archiving options